Apnimed's IPO, priced at $16 per share for an upsized 12 million shares on July 30, 2026, with trading commencing July 31 under ticker APMD, underpins the 99.6% market-implied probability of a closing market capitalization above $960 million. Positive Phase 3 results for lead candidate AD109, FDA NDA acceptance in mid-July, and a robust 2026 biotech IPO backdrop have driven strong institutional demand, reflected in the offering's expansion beyond initial targets near $600 million valuation. This skin-in-the-game consensus from Polymarket traders prices in sustained momentum through the August 3 closing. Scenarios that could still shift outcomes include unexpected regulatory delays, weaker-than-expected aftermarket trading volumes, or macroeconomic shifts raising risk aversion in healthcare equities.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว$960M+ 99.6%
$600M-$720M 1.0%
$480M-$600M <1%
$840M-$960M <1%
$2,887 ปริมาณ
$2,887 ปริมาณ
Jul 30, 2026
<$480M
No
$480M-$600M
No
$600M-$720M
No
$720M-$840M
No
$840M-$960M
No
$960M+
Yes
No IPO before October 2026
No
$960M+ 99.6%
$600M-$720M 1.0%
$480M-$600M <1%
$840M-$960M <1%
$2,887 ปริมาณ
$2,887 ปริมาณ
Jul 30, 2026
<$480M
$182 ปริมาณ
No
$480M-$600M
$392 ปริมาณ
No
$600M-$720M
$759 ปริมาณ
No
$720M-$840M
$237 ปริมาณ
No
$840M-$960M
$511 ปริมาณ
No
$960M+
$611 ปริมาณ
Yes
No IPO before October 2026
$194 ปริมาณ
No
This market will resolve based on Apnimed's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Apnimed's IPO, priced at $16 per share for an upsized 12 million shares on July 30, 2026, with trading commencing July 31 under ticker APMD, underpins the 99.6% market-implied probability of a closing market capitalization above $960 million. Positive Phase 3 results for lead candidate AD109, FDA NDA acceptance in mid-July, and a robust 2026 biotech IPO backdrop have driven strong institutional demand, reflected in the offering's expansion beyond initial targets near $600 million valuation. This skin-in-the-game consensus from Polymarket traders prices in sustained momentum through the August 3 closing. Scenarios that could still shift outcomes include unexpected regulatory delays, weaker-than-expected aftermarket trading volumes, or macroeconomic shifts raising risk aversion in healthcare equities.
This market will resolve based on Apnimed's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ตลาดเปิดเมื่อ: Jul 29, 2026, 6:20 PM ET
ปริมาณการซื้อขาย
$2,887วันสิ้นสุด
Jul 31, 2026ตลาดเปิดเมื่อ
Jul 29, 2026, 6:20 PM ETResolver
0x69c47De9D...เสนอผลลัพธ์แล้ว: No
ไม่มีการคัดค้าน
ผลลัพธ์สุดท้าย: No
This market will resolve based on Apnimed's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Apnimed's IPO, priced at $16 per share for an upsized 12 million shares on July 30, 2026, with trading commencing July 31 under ticker APMD, underpins the 99.6% market-implied probability of a closing market capitalization above $960 million. Positive Phase 3 results for lead candidate AD109, FDA NDA acceptance in mid-July, and a robust 2026 biotech IPO backdrop have driven strong institutional demand, reflected in the offering's expansion beyond initial targets near $600 million valuation. This skin-in-the-game consensus from Polymarket traders prices in sustained momentum through the August 3 closing. Scenarios that could still shift outcomes include unexpected regulatory delays, weaker-than-expected aftermarket trading volumes, or macroeconomic shifts raising risk aversion in healthcare equities.
This market will resolve based on Apnimed's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ปริมาณการซื้อขาย
$2,887วันสิ้นสุด
Jul 31, 2026ตลาดเปิดเมื่อ
Jul 29, 2026, 6:20 PM ETResolver
0x69c47De9D...เสนอผลลัพธ์แล้ว: No
ไม่มีการคัดค้าน
ผลลัพธ์สุดท้าย: No
Apnimed's IPO, priced at $16 per share for an upsized 12 million shares on July 30, 2026, with trading commencing July 31 under ticker APMD, underpins the 99.6% market-implied probability of a closing market capitalization above $960 million. Positive Phase 3 results for lead candidate AD109, FDA NDA acceptance in mid-July, and a robust 2026 biotech IPO backdrop have driven strong institutional demand, reflected in the offering's expansion beyond initial targets near $600 million valuation. This skin-in-the-game consensus from Polymarket traders prices in sustained momentum through the August 3 closing. Scenarios that could still shift outcomes include unexpected regulatory delays, weaker-than-expected aftermarket trading volumes, or macroeconomic shifts raising risk aversion in healthcare equities.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย